Today, a wide spectrum of nanomedicines is being developed for the diagnosis, prevention and treatment of disease. Recent breakthroughs include the delivery of small molecules, therapeutic proteins or peptides, and great progress has been made in the material design and targeting of nanocarriers to specific tissues or across biological barriers. However, converting the strategies into products is still challenging, and many nanomedicines fail to comply with the market requirements or during the clinical trials.
This thematic issue aims to present recent research in the design, manufacture and testing of nanomedicines. Potential contributions may include, but are not limited to the following topics:
This thematic issue is dedicated to Prof. Dr. Jörg Kreuter, a pioneer of this whole research area, whose contributions have been widely recognized. With more than 300 publications, he has shaped pharmaceutical nanotechnology for the last 40 years.
Submission is OPEN – Submission Deadline: June 30, 2019
Beilstein J. Nanotechnol. 2019, 10, 811–822, doi:10.3762/bjnano.10.81
Beilstein J. Nanotechnol. 2019, 10, 1002–1015, doi:10.3762/bjnano.10.101